46 / 56
KEYNOTE 059 Cohort 1
Refractory setting
PD-L1 positive
PD-L1 expression unknown
PD-L1 negative
Change From Baseline, %
95 patients (42%) experienced a reduction
in target lesion size
–140
–120
–100
–80
–60
–40
–20
0
20
40
60
80
100
120
140
30% decrease
20% increase
Median (range) duration of response: 14.2 (2.4-
19.4+) months
a
Only patients with measurable disease per RECIST v1.1 by central review at baseline who had ≥1 postbaseline assessment were included (n = 223); assessment was nonevaluable in 1 patient.
b
Longitudinal change in the sum of the longest target lesion diameters from baseline in responders (n = 31).
+No progressive disease at last disease assessment.
Data cutoff: April 21, 2017.
Change From Baseline, %
Time Since Treatment Initiation, months
20% increase
30% decrease
On-treatment responder
Discontinued responder
0
2
4
6
8
10
12
14
16
18
20
22
24
–100
–80
–60
–40
–20
0
20
40
60
80
100
120
140
Best Percentage Change in All Patients (n = 224)
a
Longitudinal Change in Responders (n = 31)
b
Kang ESMO GI 2017
ORR
11.6% (all)
57.1% (MSI-H)
15.5% (PD-L1 pos)